Palvella Therapeutics (PVLA) Accumulated Expenses (2013 - 2026)

Palvella Therapeutics (PVLA) has reported Accumulated Expenses for 14 consecutive years, with $3.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 35.06% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $3.5 million (up 35.06% YoY), while the FY2025 annual figure was $1.9 million, down 65.02% from the prior year.
• Accumulated Expenses advanced to $3.5 million in Q1 2026 per PVLA's latest filing, from $1.9 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $14.1 million in Q1 2022 and bottomed at $175000.0 in Q4 2023.
• Historically, Accumulated Expenses has averaged $6.0 million across 5 years, with a median of $3.5 million in 2026.
• Annual changes were most pronounced in 2023 — Accumulated Expenses plunged 98.37% — and 2024, when it jumped 3028.0%.
• Palvella Therapeutics' Accumulated Expenses stood at $10.7 million in 2022, then slumped by 98.37% to $175000.0 in 2023, then surged by 3028.0% to $5.5 million in 2024, then slumped by 65.02% to $1.9 million in 2025, then surged by 80.84% to $3.5 million in 2026.
• Business Quant data shows PVLA's Accumulated Expenses at $3.5 million in Q1 2026, $1.9 million in Q4 2025, and $1.2 million in Q3 2025.